{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:27:17Z","timestamp":1793647637076,"version":"4.5.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Provincial Medical and Health Science and Technology Project","award":["2021KY576"],"award-info":[{"award-number":["2021KY576"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-026-02106-4","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T02:54:17Z","timestamp":1773024857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Meta-analysis of the association between CTCs and survival outcomes in urothelial carcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Qinfei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanai","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"10391","key":"2106_CR1","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365.","journal-title":"Lancet"},{"issue":"19","key":"2106_CR2","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.22.01792","volume":"41","author":"T Powles","year":"2023","unstructured":"Powles T, Park SH, Caserta C, et al. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After \u2265\u20092 Years of Follow-Up. J Clin Oncol. 2023;41(19):3486\u201392.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2106_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15(1):131.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2106_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41571-023-00781-y","volume":"20","author":"R Lawrence","year":"2023","unstructured":"Lawrence R, Watters M, Davies CR, et al. Circulating tumour cells for early detection of clinically relevant cancer. Nat Rev Clin Oncol. 2023;20(7):487\u2013500.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2106_CR5","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1158\/1078-0432.CCR-20-3587","volume":"27","author":"A Goldkorn","year":"2021","unstructured":"Goldkorn A, Tangen C, Plets M, et al. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). Clin Cancer Res. 2021;27(7):1967\u201373.","journal-title":"Clin Cancer Res"},{"key":"2106_CR6","doi-asserted-by":"crossref","unstructured":"Chiang PJ, Xu T, Cha TL et al. Programmed cell death ligand 1 expression in circulating tumor cells as a predictor of treatment response in patients with urothelial carcinoma. Biology (Basel). 2021;10(7):674.","DOI":"10.3390\/biology10070674"},{"issue":"5","key":"2106_CR7","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.juro.2015.06.099","volume":"194","author":"T Klatte","year":"2015","unstructured":"Klatte T, Seitz C, Rink M, et al. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. J Urol. 2015;194(5):1456\u201362.","journal-title":"J Urol"},{"key":"2106_CR8","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"2","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;2:g7647.","journal-title":"BMJ"},{"issue":"4","key":"2106_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/BLC-160069","volume":"2","author":"E Fina","year":"2016","unstructured":"Fina E, Necchi A, Giannatempo P, et al. Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma. Bladder Cancer. 2016;2(4):395\u2013403.","journal-title":"Bladder Cancer"},{"issue":"10","key":"2106_CR10","doi-asserted-by":"publisher","first-page":"e6069","DOI":"10.1016\/j.urolonc.2017.05.021","volume":"35","author":"J Abrahamsson","year":"2017","unstructured":"Abrahamsson J, Aaltonen K, Engilbertsson H, et al. Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival. Urol Oncol. 2017;35(10):e6069\u201360616.","journal-title":"Urol Oncol"},{"issue":"4","key":"2106_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.urology.2011.05.045","volume":"78","author":"TW Flaig","year":"2011","unstructured":"Flaig TW, Wilson S, Van Bokhoven A, et al. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology. 2011;78(4):863\u20137.","journal-title":"Urology"},{"issue":"2","key":"2106_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ijc.30445","volume":"140","author":"A Soave","year":"2017","unstructured":"Soave A, Riethdorf S, Dahlem R, et al. A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. Int J Cancer. 2017;140(2):381\u20139.","journal-title":"Int J Cancer"},{"key":"2106_CR13","doi-asserted-by":"publisher","first-page":"802188","DOI":"10.3389\/fonc.2021.802188","volume":"11","author":"X Yang","year":"2021","unstructured":"Yang X, Lv J, Zhou Z, et al. Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity. Front Oncol. 2021;11:802188.","journal-title":"Front Oncol"},{"issue":"3","key":"2106_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s13402-023-00785-x","volume":"46","author":"D Jin","year":"2023","unstructured":"Jin D, Qian L, Xia J, et al. In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy. Cell Oncol (Dordr). 2023;46(3):793\u20137.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"2106_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","volume":"6","author":"D Lin","year":"2021","unstructured":"Lin D, Shen L, Luo M, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6(1):404.","journal-title":"Signal Transduct Target Ther"},{"key":"2106_CR16","doi-asserted-by":"publisher","first-page":"104237","DOI":"10.1016\/j.ebiom.2022.104237","volume":"83","author":"Z Deng","year":"2022","unstructured":"Deng Z, Wu S, Wang Y, et al. Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine. 2022;83:104237.","journal-title":"EBioMedicine"},{"key":"2106_CR17","doi-asserted-by":"crossref","unstructured":"Lu J, Kornmann M, Traub B. Role of epithelial to mesenchymal transition in colorectal cancer. Int J Mol Sci. 2023;24(19):14815.","DOI":"10.3390\/ijms241914815"},{"issue":"8","key":"2106_CR18","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1016\/j.apsb.2024.04.034","volume":"14","author":"M Tang","year":"2024","unstructured":"Tang M, Zhang Z, Wang P, et al. Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells. Acta Pharm Sin B. 2024;14(8):3457\u201375.","journal-title":"Acta Pharm Sin B"},{"issue":"35","key":"2106_CR19","doi-asserted-by":"publisher","first-page":"12159","DOI":"10.1021\/acs.analchem.2c02556","volume":"94","author":"Y Wu","year":"2022","unstructured":"Wu Y, Zhou Y, Paul R, et al. Adaptable Microfluidic Vessel-on-a-Chip Platform for Investigating Tumor Metastatic Transport in Bloodstream. Anal Chem. 2022;94(35):12159\u201366.","journal-title":"Anal Chem"},{"issue":"1","key":"2106_CR20","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-021-24386-0","volume":"12","author":"YF Sun","year":"2021","unstructured":"Sun YF, Wu L, Liu SP, et al. Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. Nat Commun. 2021;12(1):4091.","journal-title":"Nat Commun"},{"key":"2106_CR21","doi-asserted-by":"publisher","first-page":"722078","DOI":"10.3389\/fgene.2021.722078","volume":"12","author":"Y Chang","year":"2021","unstructured":"Chang Y, Wang Y, Li B, et al. Whole-Exome Sequencing on Circulating Tumor Cells Explores Platinum-Drug Resistance Mutations in Advanced Non-small Cell Lung Cancer. Front Genet. 2021;12:722078.","journal-title":"Front Genet"},{"issue":"1","key":"2106_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41392-024-01960-8","volume":"9","author":"J Cai","year":"2024","unstructured":"Cai J, Zhang W, Lu Y, et al. Single-cell exome sequencing reveals polyclonal seeding and TRPS1 mutations in colon cancer metastasis. Signal Transduct Target Ther. 2024;9(1):247.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2106_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41392-024-01938-6","volume":"9","author":"X Gu","year":"2024","unstructured":"Gu X, Wei S, Lv X. Circulating tumor cells: from new biological insights to clinical practice. Signal Transduct Target Ther. 2024;9(1):226.","journal-title":"Signal Transduct Target Ther"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02106-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02106-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02106-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:55:09Z","timestamp":1776250509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02106-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2106"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02106-4","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"12 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This systematic review and meta-analysis is based exclusively on data extracted from previously published studies, and does not involve the collection or use of any new, identifiable personal data. Therefore, the Ethics Committee of Zhejiang Cancer Hospital has granted an exemption for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}